{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:55:13Z","timestamp":1793548513757,"version":"4.5.0"},"reference-count":234,"publisher":"Centers for Disease Control MMWR Office","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr7203a1","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T10:08:36Z","timestamp":1693908516000},"page":"1-39","source":"Crossref","is-referenced-by-count":173,"title":["Pneumococcal Vaccine for Adults Aged \u226519 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023"],"prefix":"10.15585","volume":"72","author":[{"given":"Miwako","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pilishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Leidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gierke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Campos-Outcalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Poehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41579-018-0001-8","article-title":"Streptococcus pneumoniae: transmission, colonization and invasion.","volume":"16","author":"Weiser","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S1473-3099(04)00938-7","article-title":"Streptococcus pneumoniae colonisation: the key to pneumococcal disease.","volume":"4","author":"Bogaert","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R3","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R4","doi-asserted-by":"publisher","first-page":"824788","DOI":"10.3389\/fcimb.2022.824788","article-title":"Diverse mechanisms of protective anti-pneumococcal antibodies.","volume":"12","author":"Gingerich","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R5","doi-asserted-by":"publisher","first-page":"e00937\u201320","DOI":"10.1128\/mBio.00937-20","article-title":"A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus.","volume":"11","author":"Ganaie","year":"2020","journal-title":"MBio"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R6","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.3390\/ijms22094580","article-title":"Carbon source-dependent changes of the structure of Streptococcus pneumoniae capsular polysaccharide with serotype 6F.","volume":"22","author":"Werren","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R7","doi-asserted-by":"publisher","first-page":"e0054021","DOI":"10.1128\/JCM.00540-21","article-title":"Structural, genetic, and serological elucidation of Streptococcus pneumoniae serogroup 24 serotypes: discovery of a new serotype, 24C, with a variable capsule structure.","volume":"59","author":"Ganaie","year":"2021","journal-title":"J Clin Microbiol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R8","first-page":"1","article-title":"Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"49","author":"Advisory Committee on Immunization Practices","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R10","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children\u2014use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R11","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"61","author":"CDC","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R12","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R13","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the Advisory Committee on Immunization Practices.","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R15","unstructured":"Kroger A, Bahta L, Hunter P. Vaccine recommendations and guidance of the ACIP: general best practice guidelines for immunization: altered immunocompetence. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/immunocompetence.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022.","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R18","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R19","unstructured":"CDC. Evidence-based recommendations\u2014GRADE. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/about-grade.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R20","first-page":"327","article-title":"New framework (GRADE) for development of evidence-based recommendations by the Advisory Committee on Immunization Practices.","volume":"61","author":"CDC","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R21","unstructured":"CDC. GRADE: 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged 19\u201364 years with underlying medical conditions or other risk factors. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/pneumo-PCV20-risk-based.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R22","unstructured":"CDC. GRADE: 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged \u226565 years. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/pneumo-PCV20-age-based.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R23","unstructured":"CDC. GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults aged 19\u201364 years with underlying medical conditions or other risk factors. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/pneumo-PCV15-PPSV23-risk-based.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R24","unstructured":"CDC. GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults aged \u226565 years. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/pneumo-PCV15-PPSV23-age-based.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.15585\/mmwr.mm6745a4","article-title":"Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices.","volume":"67","author":"Lee","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R26","unstructured":"CDC. Evidence to recommendations frameworks. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/etr.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R27","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R28","unstructured":"CDC. Vaccine Safety Datalink (VSD). Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciac100","article-title":"Reemergence of invasive pneumococcal disease in Germany during the spring and summer of 2021.","volume":"75","author":"Perniciaro","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R30","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3201\/eid2808.220304","article-title":"Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic. England.","volume":"28","author":"Bertran","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1099\/0022-1317-51-2-98","article-title":"The pneumococcus: carriage, disease and conjugate vaccines.","volume":"51","author":"Obaro","year":"2002","journal-title":"J Med Microbiol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jinf.2020.06.028","article-title":"Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: a systematic review of prevalence and individual participant data meta-analysis of risk factors.","volume":"81","author":"Smith","year":"2020","journal-title":"J Infect"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R33","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","article-title":"Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data.","volume":"3","author":"Brueggemann","year":"2021","journal-title":"Lancet Digit Health"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R34","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1128\/JCM.41.11.4966-4970.2003","article-title":"Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates.","volume":"41","author":"Brueggemann","year":"2003","journal-title":"J Clin Microbiol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R35","doi-asserted-by":"publisher","first-page":"e2218959","DOI":"10.1001\/jamanetworkopen.2022.18959","article-title":"Association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral infections among children in France.","volume":"5","author":"Rybak","year":"2022","journal-title":"JAMA Netw Open"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R36","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1093\/cid\/ciab1014","article-title":"Decline in pneumococcal disease in young children during the coronavirus disease 2019 (COVID-19) pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: a prospective cohort study.","volume":"75","author":"Danino","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R37","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults.","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s12913-018-3529-4","article-title":"Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008\u20132014.","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R39","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.vaccine.2019.10.101","article-title":"Rates of hospitalization for community-acquired pneumonia among US adults: a systematic review.","volume":"38","author":"McLaughlin","year":"2020","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R40","doi-asserted-by":"publisher","first-page":"S738","DOI":"10.1093\/ofid\/ofaa439.1655","article-title":"Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on non-bacteremic pneumococcal pneumonia (NBPP) among adults in the United States, 2013\u20132017.","volume":"7","author":"Gierke","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R41","unstructured":"Self WH, Whitney C, Baughman AL,  Incidence of pneumococcal pneumonia hospitalizations during the COVID-19 pandemic in Tennessee and Georgia: results from the PNEUMO study. Presented at 12th International Symposium on Pneumococci and Pneumococcal Diseases; Toronto, ON, Canada, June 21, 2022. https:\/\/info.kenes.com\/flip\/isppd22\/"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R42","unstructured":"CDC. Active Bacterial Core surveillance (ABCs): methodology. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/abcs\/methodology\/index.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R43","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/cid\/ciz739","article-title":"Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions\u2014United States.","volume":"70","author":"Ahmed","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R44","unstructured":"Gierke R. Current epidemiology of pneumococcal disease, United States\u20142019 updates. Presented at the Advisory Committee of Immunization Practices meeting, Atlanta, GA, June 25, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/02-Pneumococcal-Gierke-508.pdf"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R45","unstructured":"CDC. ABCs Bact Facts interactive data dashboard [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https:\/\/www.cdc.gov\/abcs\/bact-facts-interactive-dashboard.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R46","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/j.vaccine.2019.04.087","article-title":"Pneumococcal epidemiology among US adults hospitalized for community-acquired pneumonia.","volume":"37","author":"Isturiz","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/infdis\/jiad028","article-title":"Changes in the incidence of invasive bacterial disease during the COVID-19 pandemic in the United States, 2014\u20132020.","volume":"227","author":"Prasad","year":"2023","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R48","unstructured":"Hoehner J, Razzaghi H, Williams WW,  Pneumococcal vaccination among U.S. Medicare beneficiaries aged \u226565 years, 2010\u20132019. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/pcv13-medicare-beneficiaries-2010-2019.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","article-title":"Surveillance of vaccination coverage among adult populations\u2014United States, 2018.","volume":"70","author":"Lu","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R50","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1016\/j.vaccine.2022.06.068","article-title":"Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.","volume":"40","author":"Ostropolets","year":"2022","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R51","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/21645515.2018.1564434","article-title":"Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States.","volume":"15","author":"McLaughlin","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R52","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ehjqcco\/qcaa030","article-title":"Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis.","volume":"7","author":"Marques Antunes","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R54","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/1469-0691.12182","article-title":"Invasive pneumococcal disease in patients with an underlying pulmonary disorder.","volume":"19","author":"Inghammar","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R55","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1513\/AnnalsATS.202004-352OC","article-title":"Inhaled corticosteroids use and risk of invasive pneumococcal disease in a population-based study.","volume":"17","author":"Tor\u00e9n","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R56","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality.","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R57","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cmi.2019.06.025","article-title":"Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes.","volume":"26","author":"Bordon","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R58","first-page":"1","article-title":"Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"46","author":"CDC","year":"1997","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R59","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1056\/NEJMoa044113","article-title":"Asthma as a risk factor for invasive pneumococcal disease.","volume":"352","author":"Talbot","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R60","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).","volume":"59","author":"CDC;","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R61","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2337\/dc08-0138","article-title":"Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study.","volume":"31","author":"Kornum","year":"2008","journal-title":"Diabetes Care"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R62","doi-asserted-by":"publisher","first-page":"678771","DOI":"10.3389\/fimmu.2021.678771","article-title":"A bittersweet response to infection in diabetes; targeting neutrophils to modify inflammation and improve host immunity.","volume":"12","author":"Dowey","year":"2021","journal-title":"Front Immunol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/dmrr.682","article-title":"Common infections in diabetes: pathogenesis, management and relationship to glycaemic control.","volume":"23","author":"Peleg","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R64","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MAJ.0b013e31823ede77","article-title":"Alcohol abuse, the alveolar macrophage and pneumonia.","volume":"343","author":"Mehta","year":"2012","journal-title":"Am J Med Sci"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R65","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.4049\/jimmunol.1002885","article-title":"Alcohol suppresses the granulopoietic response to pulmonary Streptococcus pneumoniae infection with enhancement of STAT3 signaling.","volume":"186","author":"Siggins","year":"2011","journal-title":"J Immunol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R66","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1111\/j.1530-0277.2010.01291.x","article-title":"Acute alcohol intoxication impairs the hematopoietic precursor cell response to pneumococcal pneumonia.","volume":"34","author":"Raasch","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R67","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review.","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R68","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1017\/S0950268810000774","article-title":"Alcohol consumption as a risk factor for pneumonia: a systematic review and meta-analysis.","volume":"138","author":"Samokhvalov","year":"2010","journal-title":"Epidemiol Infect"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R69","doi-asserted-by":"publisher","first-page":"ofu024","DOI":"10.1093\/ofid\/ofu024","article-title":"Rates of pneumococcal disease in adults with chronic medical conditions.","volume":"1","author":"Shea","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R70","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s11938-019-00229-2","article-title":"Infections in Cirrhosis.","volume":"17","author":"Ekpanyapong","year":"2019","journal-title":"Curr Treat Options Gastroenterol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R71","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/liv.13645","article-title":"Infections complicating cirrhosis.","volume":"38","author":"Piano","year":"2018","journal-title":"Liver Int"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R72","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1056\/NEJMoa031101","article-title":"Risk of bacterial meningitis in children with cochlear implants.","volume":"349","author":"Reefhuis","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R73","first-page":"931","article-title":"Pneumococcal vaccination for cochlear implant recipients.","volume":"51","author":"CDC.","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R74","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1542\/peds.2005-0824","article-title":"Bacterial meningitis among children with cochlear implants beyond 24 months after implantation.","volume":"117","author":"Biernath","year":"2006","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R75","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1093\/cid\/ciz649","article-title":"Community-acquired bacterial meningitis in adults with cerebrospinal fluid leakage.","volume":"70","author":"er Horst","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R76","doi-asserted-by":"publisher","first-page":"e2545","DOI":"10.1093\/cid\/ciaa1623","article-title":"Recurrent community-acquired bacterial meningitis in adults.","volume":"73","author":"er Horst","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R77","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1016\/j.vaccine.2016.07.003","article-title":"Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults.","volume":"34","author":"Baxter","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R78","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(10)61493-6","article-title":"Post-splenectomy and hyposplenic states.","volume":"378","author":"Di Sabatino","year":"2011","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R79","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease.","volume":"3","author":"Kato","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R80","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fped.2019.00339","article-title":"Safety and efficacy of pneumococcal vaccination in pediatric nephrotic syndrome.","volume":"7","author":"Goonewardene","year":"2019","journal-title":"Front Pediatr"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R81","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Kidney Disease: Improving Global Outcomes","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1684\/ecn.2009.0153","article-title":"Antibody response to pneumococcal capsular polysaccharide vaccination in patients with chronic kidney disease.","volume":"20","author":"Mahmoodi","year":"2009","journal-title":"Eur Cytokine Netw"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R83","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/j.ajkd.2019.06.014","article-title":"Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation.","volume":"75","author":"Krueger","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R84","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1128\/CVI.00153-16","article-title":"Immunogenicity of 13-valent conjugate pneumococcal vaccine in patients 50 years and older with end-stage renal disease and on dialysis.","volume":"23","author":"Mitra","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R85","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/cid\/civ803","article-title":"Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs.","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R86","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","article-title":"Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis.","volume":"24","author":"van Aalst","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R87","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1128\/CVI.00721-15","article-title":"Pneumococcal vaccination in high-risk individuals: are we doing it right?","volume":"23","author":"Papadatou","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R88","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1468-1293.2010.00892.x","article-title":"The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review.","volume":"12","author":"Pedersen","year":"2011","journal-title":"HIV Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R89","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/acr.22757","article-title":"Association of low B cell count and IgG levels with infection, and poor vaccine response with all-cause mortality in an immunosuppressed vasculitis population.","volume":"68","author":"David Morgan","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R90","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.1016\/j.vaccine.2018.08.069","article-title":"Pneumococcal vaccination in adult solid organ transplant recipients: a review of current evidence.","volume":"36","author":"Dendle","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R91","unstructured":"Kotton CN, Kroger AT, Freedman DO. Travelers with additional considerations [Chapter 5]. In: CDC Yellow Book 2020. New York, NY: Oxford University Press; 2019."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R92","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R93","doi-asserted-by":"publisher","first-page":"220055","DOI":"10.1183\/16000617.0055-2022","article-title":"Obesity, leptin and host defence of Streptococcus pneumoniae: the case for more human research.","volume":"31","author":"Hales","year":"2022","journal-title":"Eur Respir Rev"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R94","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fendo.2019.00071","article-title":"Influence of obesity on pneumococcus infection risk in the elderly.","volume":"10","author":"Frasca","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R95","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/14760584.2021.1966301","article-title":"Is there a need for pneumococcal vaccination programs for the homeless to prevent invasive pneumococcal disease?","volume":"20","author":"Tyrrell","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R96","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/infdis\/jiaa501","article-title":"Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico.","volume":"223","author":"Beall","year":"2021","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R97","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3201\/eid2510.181408","article-title":"Risk for invasive streptococcal infections among adults experiencing homelessness, Anchorage, Alaska, USA, 2002\u20132015.","volume":"25","author":"Mosites","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R98","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/occmed\/kqs055","article-title":"Vaccinating welders against pneumonia.","volume":"62","author":"Palmer","year":"2012","journal-title":"Occup Med (Lond)"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R99","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajim.22934","article-title":"Pneumococcal vaccination for welders: global deployment within a multi-national corporation.","volume":"62","author":"Donoghue","year":"2019","journal-title":"Am J Ind Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R100","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.1016\/j.ijid.2010.02.2268","article-title":"Welders are at increased risk for invasive pneumococcal disease.","volume":"14","author":"Wong","year":"2010","journal-title":"Int J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R101","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3201\/eid1811.120454","article-title":"Streptococcus pneumoniae serotype 15A in psychiatric unit, Rhode Island, USA, 2010\u20132011.","volume":"18","author":"Fleming-Dutra","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R102","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3201\/eid2707.203678","article-title":"Pneumococcal disease outbreak at a state prison, Alabama, USA, September 1\u2013October 10, 2018.","volume":"27","author":"Sanchez","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R103","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/NEJM199409083311004","article-title":"An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail.","volume":"331","author":"Hoge","year":"1994","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R104","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/501717","article-title":"Streptococcus pneumoniae serotype 4 outbreak in a home for the aged: report and review of recent outbreaks.","volume":"21","author":"Gleich","year":"2000","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R105","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/502148","article-title":"A preventable outbreak of pneumococcal pneumonia among unvaccinated nursing home residents in New Jersey during 2001.","volume":"24","author":"Tan","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R106","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1056\/NEJM199806253382601","article-title":"An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents.","volume":"338","author":"Nuorti","year":"1998","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R107","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jinf.2019.10.009","article-title":"Outbreaks of severe pneumococcal disease in closed settings in the conjugate vaccines era, 2010\u20132018: a systematic review to inform national guidance in the UK.","volume":"79","author":"Amin-Chowdhury","year":"2019","journal-title":"J Infect"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R108","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1473-3099(10)70281-4","article-title":"Effective management in clusters of pneumococcal disease: a systematic review.","volume":"11","author":"Basarab","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R109","doi-asserted-by":"crossref","unstructured":"Siegel J, Rhinehart E, Jackson M, Chlarello L;Healthcare Infection Control Practice Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Atlanta, GA: US Department of Health and Human Services, CDC; 2007. https:\/\/www.cdc.gov\/infectioncontrol\/guidelines\/isolation\/index.html","DOI":"10.1016\/j.ajic.2007.10.007"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R110","doi-asserted-by":"publisher","first-page":"e1006665","DOI":"10.1371\/journal.ppat.1006665","article-title":"The immunological mechanisms that control pneumococcal carriage.","volume":"13","author":"Jochems","year":"2017","journal-title":"PLoS Pathog"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R111","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1164\/rccm.201503-0542OC","article-title":"First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial.","volume":"192","author":"Collins","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R112","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/cid\/ciw147","article-title":"Multistate outbreak of respiratory infections among unaccompanied children, June 2014\u2013July 2014.","volume":"63","author":"Tomczyk","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R113","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1469-0691.12320","article-title":"Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.","volume":"19","author":"Durando","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R115","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/blood-2006-01-009282","article-title":"CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.","volume":"108","author":"Kelly","year":"2006","journal-title":"Blood"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R116","unstructured":"Vaxneuvance [Package Insert]. Rahway, NJ: Merck; 2022."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R117","unstructured":"Prevnar20 [Package Insert]. New York, NY: Pfizer; 2021."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R118","unstructured":"Prevnar13 [Package Insert.] New York, NY: Pfizer; 2017."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R119","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1016\/j.vaccine.2007.04.017","article-title":"Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults.","volume":"25","author":"Cook","year":"2007","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R120","unstructured":"Pneumovax23 [Package Insert.] Rahway, NJ: Merck; 2020."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R121","doi-asserted-by":"publisher","first-page":"e0169368","DOI":"10.1371\/journal.pone.0169368","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis.","volume":"12","author":"Falkenhorst","year":"2017","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R122","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/thx.2005.043323","article-title":"Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.","volume":"61","author":"Alfageme","year":"2006","journal-title":"Thorax"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R123","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/S0264-410X(99)00069-9","article-title":"Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older.","volume":"17","author":"Honkanen","year":"1999","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R124","doi-asserted-by":"publisher","first-page":"c1004","DOI":"10.1136\/bmj.c1004","article-title":"Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial.","volume":"340","author":"Maruyama","year":"2010","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R125","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.vaccine.2006.09.018","article-title":"Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.","volume":"25","author":"Ortqvist","year":"2007","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R126","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1101\/2022.10.06.22280772","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults.","volume":"12","author":"Farrar","year":"2023","journal-title":"Pathogens"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R127","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1016\/j.vaccine.2019.04.017","article-title":"Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study.","volume":"37","author":"Kim","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R128","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/infdis\/jiab474","article-title":"Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study.","volume":"225","author":"Heo","year":"2022","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R129","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/cid\/ciu002","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged \u226560 years: 3 years of follow-up in the CAPAMIS study.","volume":"58","author":"Ochoa-Gondar","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R130","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.vaccine.2009.01.013","article-title":"Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.","volume":"27","author":"Vila-Corcoles","year":"2009","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R131","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(00)02377-1","article-title":"23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.","volume":"355","author":"French","year":"2000","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R132","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1001\/archinte.160.17.2633","article-title":"Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients.","volume":"160","author":"Breiman","year":"2000","journal-title":"Arch Intern Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R133","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.vaccine.2003.10.030","article-title":"Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.","volume":"22","author":"Hung","year":"2004","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R134","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1001\/archinte.165.13.1533","article-title":"Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.","volume":"165","author":"Grau","year":"2005","journal-title":"Arch Intern Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R135","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/01.aids.0000206507.54901.84","article-title":"Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990\u20132003.","volume":"20","author":"Barry","year":"2006","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R136","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1471-2334-7-119","article-title":"Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study.","volume":"7","author":"Veras","year":"2007","journal-title":"BMC Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R137","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","article-title":"Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R138","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales.","volume":"6","author":"Djennad","year":"2019","journal-title":"EClinicalMedicine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R139","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1016\/j.vaccine.2013.09.049","article-title":"Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995\u20132011.","volume":"31","author":"Rudnick","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R140","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","article-title":"Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study.","volume":"17","author":"Suzuki","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R141","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.cmi.2017.08.010","article-title":"Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged \u226560 years\u2014a population-based retrospective cohort study.","volume":"24","author":"Kolditz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R142","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(07)70210-4","article-title":"Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?","volume":"7","author":"O\u2019Brien","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R143","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1186\/s12879-016-2040-y","article-title":"Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.","volume":"16","author":"Remschmidt","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R144","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/14760584.2021.1889374","article-title":"Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.","volume":"20","author":"Cripps","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R145","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.vaccine.2016.04.021","article-title":"Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990\u20132013.","volume":"34","author":"Miller","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R146","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults.","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R147","doi-asserted-by":"publisher","first-page":"S953","DOI":"10.1093\/ofid\/ofz360.2388","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in older adults.","volume":"6","author":"Lewis","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R148","unstructured":"Pilishvili T, Almendares O, Xing W,  Effectiveness of pneumococcal vaccines against invasive pneumococcal disease (IPD) among adults \u226565 years old in the United States. Presented at the International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia, April 15\u201319, 2018."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R149","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1093\/ofid\/ofy209.021","article-title":"Evaluation of pneumococcal vaccine effectiveness against invasive pneumococcal disease among US Medicare beneficiaries \u226565 years old.","volume":"5","author":"Pilishvili","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R150","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/cid\/ciy312","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design.","volume":"67","author":"McLaughlin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R151","doi-asserted-by":"publisher","first-page":"e019034","DOI":"10.1136\/bmjopen-2017-019034","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort.","volume":"8","author":"Prato","year":"2018","journal-title":"BMJ Open"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R152","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12879-018-3096-7","article-title":"Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.","volume":"18","author":"Vila-Corcoles","year":"2018","journal-title":"BMC Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R153","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/cid\/ciab1051","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against medically attended lower respiratory tract infection and pneumonia among older adults.","volume":"75","author":"Lewnard","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R154","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamainternmed.2022.5472","article-title":"Association of pneumococcal conjugate vaccine use with hospitalized pneumonia in Medicare beneficiaries 65 years or older with and without medical conditions, 2014 to 2017.","volume":"183","author":"Kobayashi","year":"2023","journal-title":"JAMA Intern Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R155","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1093\/cid\/ciy993","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of all-cause pneumonia in adults aged \u226560 years: a population-based, retrospective cohort study.","volume":"68","author":"Kolditz","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R156","doi-asserted-by":"publisher","first-page":"e221111","DOI":"10.1001\/jamanetworkopen.2022.1111","article-title":"Incidence and estimated vaccine effectiveness against hospitalizations for all-cause pneumonia among older US adults who were vaccinated and not vaccinated with 13-valent pneumococcal conjugate vaccine.","volume":"5","author":"Hsiao","year":"2022","journal-title":"JAMA Netw Open"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R157","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1016\/j.vaccine.2018.05.097","article-title":"A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.","volume":"37","author":"Gessner","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R158","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.vaccine.2018.01.049","article-title":"Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.","volume":"36","author":"Suaya","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R159","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.trivac.2016.04.004","article-title":"A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults).","volume":"5","author":"Patterson","year":"2016","journal-title":"Trials Vaccinol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R160","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1016\/j.vaccine.2016.10.052","article-title":"Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged \u226519 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012\u2013December 31, 2015.","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R161","doi-asserted-by":"publisher","first-page":"ofy100","DOI":"10.1093\/ofid\/ofy100","article-title":"Pneumococcal conjugate vaccine safety in elderly adults.","volume":"5","author":"Tseng","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R162","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1016\/j.vaccine.2018.03.012","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine\u2013na\u00efve adults \u226550 years of age.","volume":"36","author":"Ermlich","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R163","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R164","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1016\/j.vaccine.2011.05.086","article-title":"The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations.","volume":"29","author":"Said","year":"2011","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R165","doi-asserted-by":"publisher","first-page":"ofab605","DOI":"10.1093\/ofid\/ofab605","article-title":"Immunogenicity, safety, and tolerability of V114, a 15-valent pneumococcal conjugate vaccine, in immunocompetent adults aged 18\u201349 years with or without risk factors for pneumococcal disease: a randomized phase 3 trial (PNEU-DAY).","volume":"9","author":"Hammitt","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R166","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/QAD.0000000000003126","article-title":"Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.","volume":"36","author":"Mohapi","year":"2022","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R167","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1016\/j.vaccine.2021.08.038","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged\u202f\u226550\u202fyears: a randomized phase III trial (PNEU-PATH).","volume":"39","author":"Song","year":"2021","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R168","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/21645515.2018.1532250","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults \u226565 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.","volume":"15","author":"Peterson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R169","unstructured":"Food and Drug Administration. July 16, 2021 summary basis for regulatory action (Vaxneuvance). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https:\/\/www.fda.gov\/media\/151201\/download"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R170","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years.","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R171","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine\u2013naive adults 18 through 49 years of age.","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R172","doi-asserted-by":"publisher","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age.","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R173","doi-asserted-by":"publisher","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination.","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R174","unstructured":"Safety and immunogenicity of 20vPnC coadministered with SIIV in adults \u226565 years of age. https:\/\/clinicaltrials.gov\/study\/NCT04526574"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R175","unstructured":"Kobayashi M. Evidence to recommendations framework: PCV20 use among adults who previously received PCV13. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA, October 19, 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2022-10-19-20\/03-Pneumococcal-Kobayashi-508.pdf"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R176","unstructured":"Food and Drug Administration. June 8, 2021 summary basis for regulatory action (Prevnar20). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https:\/\/www.fda.gov\/media\/150388\/download"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R177","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine\u2013na\u00efve adults 60\u201364 years of age.","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R178","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.4161\/hv.27998","article-title":"Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.","volume":"10","author":"Juergens","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R179","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","article-title":"Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R180","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1016\/j.vaccine.2016.04.093","article-title":"Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.","volume":"34","author":"Frenck","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R181","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R182","unstructured":"Pfizer. B7471004\u2014Post hoc analysis by vaccination history. New York, NY: Pfizer; 2022."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R183","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/infdis\/jiu631","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine.","volume":"212","author":"Glesby","year":"2015","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R184","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/QAD.0000000000000689","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.","volume":"29","author":"Bhorat","year":"2015","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R185","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF00366446","article-title":"Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction.","volume":"1","author":"Hammarstr\u00f6m","year":"1993","journal-title":"Support Care Cancer"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R186","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/bmt.2009.254","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface.","volume":"44","author":"Tomblyn","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R187","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1016\/j.vaccine.2010.01.025","article-title":"Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial.","volume":"28","author":"Cordonnier","year":"2010","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R188","unstructured":"Merck. A study to evaluate the safety, tolerability, and immunogenicity of V114 in allogeneic hematopoietic stem cell transplant recipients (V114\u2013022\/PNEU-STEM). Rahway, NJ: Merck; 2018. https:\/\/clinicaltrials.gov\/study\/NCT03565900"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R189","unstructured":"Merck. Merck data on file, P022 clinical study report table 14.2\u20136 summary of IgG antibody responses at month 12 and month 13 after allo-HSCT. Rahway, NJ: Merck; 2022."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R190","unstructured":"Merck. Merck data on file, P022 clinical study report table 14.2\u20137 summary of OPA antibody responses at month 12 and month 13 after allo-HSCT. Rahway, NJ: Merck; 2022."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R191","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.vaccine.2018.11.053","article-title":"Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation.","volume":"37","author":"Langedijk","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R192","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1086\/598324","article-title":"Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R193","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ajh.26493","article-title":"Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation.","volume":"97","author":"Garcia Garrido","year":"2022","journal-title":"Am J Hematol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R194","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/cid\/civ287","article-title":"Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged \u22652 years: an open-label study.","volume":"61","author":"Cordonnier","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R195","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1080\/21645515.2021.1888621","article-title":"Sequential administration of Prevnar 13\u2122 and PNEUMOVAX\u2122 23 in healthy participants 50 years of age and older.","volume":"17","author":"Buchwald","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R196","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3899\/jrheum.161407","article-title":"Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: results of a randomized controlled trial.","volume":"44","author":"Nguyen","year":"2017","journal-title":"J Rheumatol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R197","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/599824","article-title":"Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska Native adults 55\u201370 years of age.","volume":"49","author":"Miernyk","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1976581","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged \u226550 years: a randomized phase 3 trial (PNEU-FLU).","volume":"18","author":"Severance","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R199","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1016\/j.vaccine.2017.09.012","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults \u226550 years of age: results from a phase III, randomized, non-inferiority trial.","volume":"35","author":"Ofori-Anyinam","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R200","unstructured":"Safety and immunogenicity study of 20vPnC when coadministered with a booster dose of BNT162b2. https:\/\/clinicaltrials.gov\/study\/NCT04887948"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R201","unstructured":"Safety, tolerability, and immunogenicity of V110 or V114 co-administered with a booster dose of mRNA-1273 in healthy adults (V110\u2013911). https:\/\/clinicaltrials.gov\/study\/NCT05158140"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R202","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550\u202fyears of age: a randomized trial.","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R203","unstructured":"Leidner A. Summary of three economic models assessing pneumococcal vaccines in US adults. Presented at the Advisory Committee for Immunization Practices meeting. Atlanta, GA, September 29, 2021."},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R204","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40121-022-00669-x","article-title":"Cost-effectiveness of newly recommended pneumococcal vaccination strategies in older underserved minority adults in the USA.","volume":"11","author":"Smith","year":"2022","journal-title":"Infect Dis Ther"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R205","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.amepre.2021.01.023","article-title":"Higher-valency pneumococcal conjugate vaccines: an exploratory cost-effectiveness analysis in U.S. seniors.","volume":"61","author":"Smith","year":"2021","journal-title":"Am J Prev Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R206","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/cid\/ciy800","article-title":"Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization.","volume":"68","author":"Pelton","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R207","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14760584.2021.1898377","article-title":"Pneumococcal vaccination coverage among adults aged 19 to 64 years with immuno-compromising conditions, cerebrospinal fluid (CSF) leaks, or cochlear implants in the US.","volume":"20","author":"Deb","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R208","unstructured":"CDC. Evidence to recommendations for PCV15 use among adults 19\u201364 years old. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/pneumo-PCV15-PPSV23-risk-based-etr.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R209","unstructured":"CDC. Evidence to recommendations for PCV20 use among adults 19\u201364 years old. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/pneumo-PCV20-risk-based-etr.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R210","unstructured":"Kroger A, Bahta L, Long S, Sanchez P. Timing and spacing of immunobiologics. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/timing.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R211","unstructured":"CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#timing-spacing-interchangeability"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R212","unstructured":"Kroger A, Bahta L, Hunter P. Contraindications and precautions. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/contraindications.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R213","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/infdis\/jiab567","article-title":"Immunogenicity of conjugated and polysaccharide pneumococcal vaccines administered during pregnancy or postpartum to women with HIV.","volume":"225","author":"Duarte","year":"2022","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R214","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1016\/j.vaccine.2007.03.021","article-title":"Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies.","volume":"25","author":"Quiambao","year":"2007","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R215","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0264-410X(02)00040-3","article-title":"Maternal immunization with pneumococcal polysaccharide vaccine in the highlands of Papua New Guinea.","volume":"20","author":"Lehmann","year":"2002","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R216","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/ajo.13002","article-title":"Birth outcomes in Aboriginal mother-infant pairs from the Northern Territory, Australia, who received 23-valent polysaccharide pneumococcal vaccination during pregnancy, 2006\u20132011: the PneuMum randomised controlled trial.","volume":"60","author":"McHugh","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R217","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2352-3018(20)30339-8","article-title":"Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial.","volume":"8","author":"Weinberg","year":"2021","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R218","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1016\/S0264-410X(03)00349-9","article-title":"Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines.","volume":"21","author":"Quiambao","year":"2003","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R219","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/cid\/ciac026","article-title":"Effect of maternal immunization with 10-valent pneumococcus conjugate vaccine (PCV-10), 23-valent pneumococcus polysaccharide vaccine, or placebo on the immunogenicity of PCV-10 in human immunodeficiency virus-exposed uninfected infants: a randomized clinical trial.","volume":"75","author":"Mussi-Pinhata","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R220","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1097\/01.inf.0000143651.54880.09","article-title":"Serotype-specific pneumococcal antibodies in breast milk of Gambian women immunized with a pneumococcal polysaccharide vaccine during pregnancy.","volume":"23","author":"Obaro","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R221","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/0264-410X(96)00009-6","article-title":"Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy.","volume":"14","author":"O\u2019Dempsey","year":"1996","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R222","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1056\/NEJMoa0708630","article-title":"Effectiveness of maternal influenza immunization in mothers and infants.","volume":"359","author":"Zaman","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R223","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1590\/S1413-86702009000200006","article-title":"Ineffectiveness for infants of immunization of mothers with pneumococcal capsular polysaccharide vaccine during pregnancy.","volume":"13","author":"Lopes","year":"2009","journal-title":"Braz J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R224","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(95)91861-2","article-title":"Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine.","volume":"346","author":"Shahid","year":"1995","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R225","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S0264-410X(01)00397-8","article-title":"Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation.","volume":"20","author":"Munoz","year":"2001","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R226","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1016\/j.vaccine.2009.04.018","article-title":"Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants.","volume":"27","author":"Almeida","year":"2009","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R227","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1016\/j.vaccine.2015.10.101","article-title":"PneuMum: impact from a randomised controlled trial of maternal 23-valent pneumococcal polysaccharide vaccination on middle ear disease amongst Indigenous infants, Northern Territory, Australia.","volume":"33","author":"Binks","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R228","unstructured":"National Institute for Allergy and Infectious Diseases. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.0. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Institute for Allergy and Infectious Diseases; 2014. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daids-ae-grading-table-v2-nov2014.pdf"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R229","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022.","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R230","unstructured":"CDC. Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https:\/\/www.cdc.gov\/vaccines\/acip\/recommendations.html"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R231","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1016\/j.vaccine.2022.05.079","article-title":"Phase 1\/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.","volume":"40","author":"Chichili","year":"2022","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R232","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R233","unstructured":"Sanofi. Study of a pneumococcal conjugate vaccine in adults aged 50 to 84 years. https:\/\/clinicaltrials.gov\/study\/NCT04583618"},{"key":"key-10.15585\/mmwr.rr7203a1-202309050940-R234","unstructured":"Jatlaoui TC, Hung M-C, Srivastav A,  Vaccination coverage among adults in the United States, National Health Interview Survey, 2019\u20132020. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/vaccination-coverage-adults-2019-2020.html#print"}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T10:08:49Z","timestamp":1693908529000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/72\/rr\/rr7203a1.htm?s_cid=rr7203a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":234,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,8]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr7203a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,8]]},"published":{"date-parts":[[2023,9,8]]}}}